Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440466 · ClinicalTrials.gov registry record · Phase 3
PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients
A Phase 3 study of Anemia and Renal Diseases, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
- 20
- Study locations
NCT00440466 is a Phase 3 study of Anemia and Renal Diseases that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 430 participants, roughly in line with the 422-participant average among 72 other Anemia trials with a reported enrollment target. The trial reports 20 study locations across 4 states.
The verdict
NCT00440466, a Phase 3 study of Anemia and Renal Diseases, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks treatment with epoetin alfa, a drug that increases red blood cell production, in patients with anemia associated with chronic kidney disease, is not less effective than treatment with epoetin alfa that is given once a week
Conditions Studied
Interventions
- DRUG epoetin alfa
Study Locations (20)
California
- - Chula Vista
- - Fountain Valley
- - Los Angeles
- - Lynwood
- - Orange
- - Riverside
- - San Dimas
- - West Hills
- - Yuba City
Florida
- - Clearwater
- - Miami
- - Pembroke Pines
- - Plantation
- - Springhill
- - Tampa
- - West Palm Beach
- - Zephyrhills
Colorado
- - Lakewood
- - Thornton
District of Columbia
- - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440466
The ClinicalTrials.gov registry entry for NCT00440466 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 422-participant average among 72 other Anemia trials with a reported enrollment target. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Anemia appearing as the primary indexed condition, and to 1 intervention - of which epoetin alfa is the first listed.
NCT00440466 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT00440466 about?
NCT00440466 is a clinical study titled "PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients". The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks treatment with epoetin alfa, a drug that increases red blood cell production, in patients with anemia associated with chronic kidney disease, is not less effective than treatment with epoetin alfa that is give...
What is the current status of trial NCT00440466?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2007-07. Estimated completion is 2009-03.
What conditions does trial NCT00440466 study?
This clinical trial studies the following conditions: Anemia, Renal Diseases.
What interventions are being tested in trial NCT00440466?
The interventions under investigation include: epoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00440466?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00440466 being conducted?
This trial has 20 study locations across California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RECRUITING · Phase 3
-
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
ACTIVE NOT RECRUITING · Phase 3
-
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ACTIVE NOT RECRUITING · Phase 3
-
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.